Madopar (Benserazide Hydrochloride, Levodopa)

Levodopa, the primary component of Madopar, is a precursor of dopamine that crosses the blood‑brain barrier. Once inside the central nervous system, it is converted to dopamine, replenishing the neurotransmitter that is deficient in Parkinson's disease. Benserazide blocks peripheral conversion, ensuring more levodopa reaches the brain.

The appropriate dose of Madopar is individualized and determined by a qualified prescriber based on the patient's clinical status, disease severity, and response to therapy. Dosage adjustments are made gradually to balance symptom control with tolerability, and patients should follow the prescribing physician's instructions precisely.

Safety data for Madopar in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any possible risk to the fetus or infant. Healthcare providers typically assess each case carefully and may recommend alternative therapies if safer options are available.

To place an order, submit an enquiry on the Madopar product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Madopar combines levodopa with benserazide, offering higher central availability of levodopa than levodopa alone and fewer peripheral side effects. Compared with dopamine agonists, it provides more robust symptom relief but may have a higher risk of motor complications such as dyskinesia. Choice of therapy depends on individual patient factors.

Madopar tablets should be stored at ambient temperature, below 25 °C, in the original blister pack or container. Protect them from moisture, excessive heat, and direct sunlight. Keep the medication out of reach of children and do not use if the packaging is damaged.

Madopar is taken orally with a full glass of water. It can be taken with or without food, although high‑protein meals may reduce absorption. Patients should follow the dosing schedule prescribed by their clinician and avoid crushing or chewing extended‑release formulations unless specifically instructed.

Serious risks include the development of dyskinesia (involuntary movements), hallucinations or other psychotic symptoms, severe orthostatic hypotension, and rare events such as neuroleptic malignant syndrome. Patients should be monitored regularly for these complications, and any sudden changes should be reported to a healthcare professional promptly.

Madopar is contraindicated in patients with known hypersensitivity to levodopa, benserazide, or any excipients, as well as those taking non‑selective MAO inhibitors. Caution is advised for individuals with narrow‑angle glaucoma, severe cardiovascular disease, or a history of malignant melanoma. A physician should evaluate suitability before initiating therapy.